Martinez-Ferrer v. Richardson-Merrell, Inc.

105 Cal. App. 3d 316, 164 Cal. Rptr. 591, 1980 Cal. App. LEXIS 1777
CourtCalifornia Court of Appeal
DecidedApril 30, 1980
DocketCiv. 55884
StatusPublished
Cited by48 cases

This text of 105 Cal. App. 3d 316 (Martinez-Ferrer v. Richardson-Merrell, Inc.) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Martinez-Ferrer v. Richardson-Merrell, Inc., 105 Cal. App. 3d 316, 164 Cal. Rptr. 591, 1980 Cal. App. LEXIS 1777 (Cal. Ct. App. 1980).

Opinion

Opinion

KAUS, P. J.

This is an appeal from a judgment for defendants after their motion for summary judgment against plaintiff Raul Martinez-Ferrer (Raul) was granted. Defendants cross appeal from the granting of plaintiff Nancy Martinez’ (Nancy) motion for new trial.

Plaintiffs’ first amended complaint alleged causes of action 1 arising from personal injuries—cataracts—resulting from Raul’s ingestion of the drug MER/29 which was manufactured and distributed by defendant Richardson-Merrell and provided to Raul by Richardson-Merrell’s salesman, defendant Leo Spengler. In the complaint, Nancy, Raul’s wife, also alleged partial loss of consortium as a result of those same injuries. Defendants’ successful motion for summary judgment was based solely on the ground that the actions were barred by the one-year statute of limitation (Code Civ. Proc., § 340, subd. 3.) Nancy’s motion for new trial was granted for technical reasons which, in view of our ruling concerning Raul, will become irrelevant.

In support of their motion for summary judgment, defendants relied mainly upon Raul’s deposition testimony. In that proceeding, Raul testified that he was a physician and surgeon who had been practicing in California since 1959. In 1960, he was suffering from a high cholesterol condition. Having read some of Richardson-Merrell’s advertising promoting its anticholesterol drug MER/29, and after a “hallway consultation” with a doctor acquaintance, Raul prescribed MER/29 for himself and began taking the drug in about March of 1960.

On September 23, 1960, Raul suddenly discovered that he was unable to read. On that date he went to ophthalmologist Leonard Rifkin. *319 Doctor Rifkin examined his eyes and discussed possible causes of the problem. Raul suggested a chemical cause, speculating that “maybe the MER/29 breaks the pre-cholesterol earlier than it should be.” Doctor Rifkin told him to stop taking all medications 2 and arranged for photographs to be taken of the interiors of his eyes. The photographs revealed macula edema—a swelling of a portion of the retina—and Doctor Rifkin diagnosed the condition as an “acute allergic reaction” of the backs of the eyes. Other eye specialists concurred in the diagnosis. Although at the time there was no known history of MER/29 producing eye problems, Raul and his doctors “assumed” that the cause of his condition was the medication; he was told to stop taking both MER/29 and the vitamins “just in case.... ”

A few weeks after the eye problems started, Raul developed a severe case of dermatitis which covered his entire body. His doctor concluded that the “likely cause” was MER/29.

During the period when he was suffering from these problems, Raul did not work for four to six weeks. The dermatitis cleared up in four or five months and, although some retinal scarring remained, his eyes got better “as the time passed.” His vision was “poor,” but he had worn eyeglasses since 1946 and he was able to resume his practice as a doctor.

Raul continued to have his eyes examined every two to three years and no further problems were found until 1976. In February 1976, opacities, or cataracts, were discovered in the capsules of his eyes. The cataracts were a permanent condition which created tunnel vision and interfered with Raul’s ability to perform surgery. Raul anticipated that he “would not be able to see for too long.” Dr. Rifkin determined that the cataracts were not “senile in character” but had been caused by MER/29. It should be stressed that the record contains no suggestion that the cataracts were wholly or partly the result of the 1960 retinal swelling—the macula edema.

Defendants also presented evidence that on December 1, 1961, Richardson-Merrell had sent a letter to all doctors in the United States warning them that a “few serious clinical injuries” had been reported in patients who had received MER/29. The letter specifically mentioned cataracts and icthyosis—a form of dermatitis—as having been reported, although it concluded that “[t]he side effects of all types reported to *320 us to date total substantially less than one percent of the patients treated.” 3 In his declaration in opposition to the motion for a summary judgment Raul states: “I did not read any of the literature referred to in [plaintiffs’ counsels’] declaration regarding MER/29 causing cataracts, since I did not, to my knowledge, have cataracts.” 4

In opposition to defendants’ motion for summary judgment, Raul declared that he had suffered “no permanent damage or injury” as a result of the 1960 problems and consequently “there was no point in bringing a lawsuit” at that time. He had “no idea” that he was developing cataracts until early in 1976.

Raul also presented a declaration by Doctor Rifkin, who stated that about six weeks after the onset of his 1960 eye problems, Raul’s vision was “fully restored.” Intermittent examinations between 1961 and 1975 revealed no sign of cataracts. Rifkin’s suggestion in 1960 that Raul’s macula edema had been caused by MER/29 was “merely a guess” on his part. All of the current eye problems, however, were due to the cataracts.

Jerome Bettman, M.D., an ophthalmologist with expertise in the etiology of cataracts—particularly as caused by MER/29—declared that he was aware of “no scientific or medical data” in existence from 1960 to 1978 which “even suggested]” that MER 29 could cause macula edema.

In granting defendants’ motion for summary judgment, the court necessarily determined that the statute of limitations had run when Raul filed his complaint on June 24, 1976.

While Raul presents various arguments which, if correct, would lead to a reversal, his first and dispositive point is this: however certain he may have been, in 1960, that his then troubles—the dermatitis and the macula edema—were caused by MER/29, if, in fact, that was not the case, no statute of limitations would have started to run. To put the *321 issue differently: unless the record demonstrates without substantial conflict that Raul would have had a case had he sued two decades ago, the summary judgment cannot stand; the first prerequisite for the running of the statute of limitations against a cause of action is the existence of such a cause.

Defendants deny this self-evident proposition and claim that the statute started to run when plaintiff knew or should have known that he had suffered injury as the probable result of MER/29, whether or not his actual or constructive knowledge was correct. In support of this thesis defendants cite Gray v. Reeves (1977) 76 Cal.App.3d 567, 577 [142 Cal.Rptr. 716]. In that case the plaintiff claimed that a drug called prednisone which he had started to take in 1968 had caused a degeneration of his hip socket. Corrective surgery was performed in 1971. Suit was not filed until 1973. The court held that the statute of limitations had run as a matter of law because the cause of the injury had been explained to plaintiff no later than January 1971, when “he clearly understood the drug prednisone

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Pooshs v. Phillip Morris USA, Inc.
561 F.3d 964 (Ninth Circuit, 2009)
Grisham v. Philip Morris U.S.A., Inc.
151 P.3d 1151 (California Supreme Court, 2007)
Girardi v. Boyles, Unpublished Decision (3-2-2006)
2006 Ohio 947 (Ohio Court of Appeals, 2006)
Crowley v. Peterson
206 F. Supp. 2d 1038 (C.D. California, 2002)
Rosenblatt v. Ernst & Young International, Ltd.
28 F. App'x 731 (Ninth Circuit, 2002)
Clark v. Baxter Healthcare Corp.
100 Cal. Rptr. 2d 223 (California Court of Appeal, 2000)
O'CONNOR v. Boeing North American, Inc.
114 F. Supp. 2d 949 (C.D. California, 2000)
Alexander v. Scheid
726 N.E.2d 272 (Indiana Supreme Court, 2000)
Rosenblatt v. Ernst & Young International, Ltd.
87 F. Supp. 2d 1048 (S.D. California, 2000)
Green v. American Pharmaceutical Co.
935 P.2d 652 (Court of Appeals of Washington, 1997)
Annette T. New v. Armour Pharmaceutical Company
58 F.3d 445 (Ninth Circuit, 1995)
Henry v. Clifford
32 Cal. App. 4th 315 (California Court of Appeal, 1995)
Ward v. Westinghouse Canada, Inc.
32 F.3d 1405 (Ninth Circuit, 1994)
Miranda v. Shell Oil Co.
17 Cal. App. 4th 1651 (California Court of Appeal, 1993)
Marinari v. Asbestos Corp., Ltd.
612 A.2d 1021 (Superior Court of Pennsylvania, 1992)
Cottle v. Superior Court
3 Cal. App. 4th 1367 (California Court of Appeal, 1992)
Miller v. Lakeside Village Condominium Assn.
1 Cal. App. 4th 1611 (California Court of Appeal, 1991)
Marsha v. v. GARDNER
231 Cal. App. 3d 265 (California Court of Appeal, 1991)
Potts v. Celotex Corp.
796 S.W.2d 678 (Tennessee Supreme Court, 1990)

Cite This Page — Counsel Stack

Bluebook (online)
105 Cal. App. 3d 316, 164 Cal. Rptr. 591, 1980 Cal. App. LEXIS 1777, Counsel Stack Legal Research, https://law.counselstack.com/opinion/martinez-ferrer-v-richardson-merrell-inc-calctapp-1980.